Verona Pharma (NASDAQ:VRNA – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $60.00 ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the shares following the “massive” Q4 revenue beat.

HC Wainwright also issued estimates for Verona Pharma’s Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.16 EPS and FY2025 earnings at ($0.08) EPS. Get ...

On Tuesday, H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares. The ...